Penn Capital Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-1,841,035
| Closed | -$27.7M | – | 323 |
|
|
2016
Q2 | $27.7M | Buy |
1,841,035
+107,048
| +6% | +$1.38M | 1.57% | 3 |
|
|
2016
Q1 | $21.1M | Buy |
1,733,987
+334,782
| +24% | +$4.69M | 1.2% | 15 |
|
|
2015
Q4 | $22.3M | Buy |
1,399,205
+216,572
| +18% | +$3.41M | 0.98% | 15 |
|
|
2015
Q3 | $18.1M | Sell |
1,182,633
-64,795
| -5% | -$1.4M | 0.95% | 15 |
|
|
2015
Q2 | $30.3M | Buy |
1,247,428
+387,556
| +45% | +$9.28M | 1.25% | 4 |
|
|
2015
Q1 | $20M | Buy |
859,872
+492,114
| +134% | +$13M | 0.79% | 32 |
|
|
2014
Q4 | $9.23M | Sell |
367,758
-264,917
| -42% | -$7.77M | 0.39% | 98 |
|
|
2014
Q3 | $19.7M | Sell |
632,675
-13,374
| -2% | -$362K | 0.82% | 29 |
|
|
2014
Q2 | $16.7M | Sell |
646,049
-30,062
| -4% | -$668K | 0.65% | 50 |
|
|
2014
Q1 | $15.8M | Sell |
676,111
-7,943
| -1% | -$174K | 0.6% | 64 |
|
|
2013
Q4 | $17.4M | Buy |
684,054
+508,086
| +289% | +$11.5M | 0.62% | 55 |
|
|
2013
Q3 | $3.59M | Sell |
175,968
-26,063
| -13% | -$580K | 0.15% | 180 |
|
|
2013
Q2 | $4.24M | Buy |
+202,031
| New | +$3.61M | 0.17% | 179 |
|
Penn Capital Management's SGNT Position: Q3 2016 in Review
Penn Capital Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 1,841,035 shares — an estimated $27.7M sold.
Penn Capital Management first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $30.3M in Q2 2015. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Penn Capital Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Penn Capital Management sold 1,841,035 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $27.7M.
- Penn Capital Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Penn Capital Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $30.3M in Q2 2015.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Penn Capital Management's 13F filing for Q3 2016, filed 15 Nov 2016.